Femasys Inc

COO John C. Canning’s 150,000‑option buy at Femasys signals insider confidence amid steep share drops, hinting at a future rally as clinical milestones hit.

CEO Kathy Lee‑Sepsick’s massive RSU buy signals strong confidence in Femasys’s future, driving investor optimism amid new Swiss partnerships and a 6.6% share gain.